Umuthi wokugoma i-Spikevax e-Canada, Europe, nase-Japan
I-Spikevax yehlukile futhi mhlawumbe iyisixazululo esisha ekulweni nobhubhane lwe-COVID-19.
I-Brand Institute iyaziqhenya ngokumemezela ubudlelwano bayo obuyimpumelelo neModerna ekuqambeni umuthi wabo wokugomela i-mRNA COVID-19: SPIKEVAX®. Igama lomkhiqizo limenyezelwe nguMnyango Wezempilo, Wezabasebenzi, Nenhlalakahle lapho i-ejensi ivuma ukushuthwa komuthi wokugoma ngoDisemba 16, 2021.
"Ithimba lonke le-Brand Institute kanye ne-Drug Safety Institute lihalalisela iModerna ngokugunyazwa yi-MHLW ngomuthi wabo wokugomela i-COVID-19 kanye nesimemezelo esihambisanayo segama lomkhiqizo we-SPIKEVAX® leMakethe YaseJapan," kusho uSihlalo kanye ne-CEO yeBrand Institute, uJames L. I-Dettore. "Isimemezelo segama lomkhiqizo we-SPIKEVAX® sibonisa ukuthi igama ligcwalisa izimfuneko zokulawula ze-MHLW zegama lomkhiqizo wokugoma elizothengiswa e-Japan."
“I-spike” ku-“SPIKEVAX” ibhekisa ku-spike glycoprotein, okungenye yezici ezibalulekile ze-SARS-CoV-2. Umuthi wokugomela i-mRNA i-SPIKEVAX® unikeza imiyalelo yokuthi amaseli akhiqize amakhophi eprotheyini ye-spike, kamuva abe yizimpokophelo zokukhiqiza amasosha omzimba alwa nawo. Ngokwenza kanjalo, umzimba uthuthukisa ukungatheleleki ekuthelelekeni ngegciwane le-SARS-CoV-2.
"Ucwaningo lwethu lokuqamba amagama lubonise ukuthi i-SPIKEVAX® yayingeyona nje into efanelekile yomkhiqizo kodwa futhi ikhumbuleka kakhulu futhi iyingqayizivele," kusho uDettore. "Igama elithi 'SPIKEVAX' linezici eziningi nezibaluli esiziphishekelayo lapho sidala igama elisha lekhemisi noma lokugoma."
I-SPIKEVAX® iphinde yamukelwa yi-European Medicines Agency (EMA) kanye ne-Health Canada. Ukugunyazwa kwegama lomkhiqizo ngamanye ama-ejensi alawulayo emhlabeni wonke kuzolandela imihlahlandlela yawo, izinqubomgomo, nezinqubo.
Mayelana ne-Brand Institute kanye nenkampani yethu ephethwe ngokugcwele, I-Drug Safety Institute
I-Brand Institute ingumholi womhlaba jikelele ekuthuthukisweni kwamagama ahlobene nemithi kanye nokunakekelwa kwezempilo, enephothifoliyo yamagama okunakekelwa kwezempilo adayiswa angaphezu kuka-3,500 cishe kumakhasimende ayi-1,000. Inkampani ibambisene ngaphezu kuka-75% womkhiqizo wemithi kanye nokugunyazwa kwamagama okungewona obunikazi emhlabeni jikelele minyaka yonke. I-Drug Safety Institute yakhiwe yizikhulu ezilawula amagama zangaphambili ezivela ezikhungweni zezempilo zikahulumeni womhlaba wonke, okuhlanganisa i-FDA, EMA, Health Canada, American Medical Association (AMA), kanye ne-World Health Organization (WHO). Laba chwepheshe bokulawula babhale ngokuhlanganyela imihlahlandlela yokubuyekeza igama ngenkathi bekanye nezinhlaka zabo, abaningi abanomthwalo wemfanelo wokuvumela (noma ukwenqaba) izicelo zamagama ebhrendi ekugcineni. Manje zisebenzela inkampani ezimele, lezi zingcweti zinikeza amakhasimende e-Brand Institute isiqondiso esihamba phambili embonini esiphathelene nokuphepha kwegama lezidakamizwa (okungukuthi, ukuvimbela amaphutha emithi), ukupakisha, nokulebula.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- “The entire Brand Institute and Drug Safety Institute Team congratulates Moderna on the MHLW’s approval of their COVID-19 vaccine booster shot and the corresponding announcement of the SPIKEVAX® brand name for the Japanese Market,”.
- “The announcement of the SPIKEVAX® brand name indicates that the name fulfills the MHLW’s regulatory requirements for a vaccine brand name to be marketed in Japan.
- Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 3,500 marketed healthcare names for nearly 1,000 clients.